Intelligent tunable CAR-T cell therapy leads the new trend

Jiayi Cheng; Mingyao Liu; Jiqin Zhang

doi:10.1016/j.synbio.2023.09.001

Intelligent tunable CAR-T cell therapy leads the new trend

Synth Syst Biotechnol. 2023 Sep 14;8(4):606-609. doi: 10.1016/j.synbio.2023.09.001. eCollection 2023 Dec.

Authors

Jiayi Cheng¹, Mingyao Liu¹, Jiqin Zhang¹

Affiliation

¹ Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.

Abstract

Adoptive transfer of T cells engineered with chimeric antigen receptor (CAR) has been proved to have robust anti-tumor effects against hematological malignancies. However, problems about safety and efficacy, such as cytokine release syndrome (CRS), T cell exhaustion and antigen escape are still raised when patients are treated with CAR-T cells. Moreover, CAR-T therapy has limited applications in treating solid tumors, owing to inefficient infiltration and poor functional persistence of CAR-T cells and diverse immunosuppression in tumor microenvironment. In order to overcome these limitations and broad its applications, multiple controllable CAR-T technologies were exploited. In this article, we review the designs of intelligent controlled CAR-T technologies and the innovations that they bring about in recent years.

Keywords: Autologous universal system; Chimeric antigen receptor T; On and off systems; Safety and efficacy; Synthetic notch system; Tumor.

Publication types

Review